JHU TRAC: Training and Supporting the Next Generation of TB Researchers
JHU TRAC:培训和支持下一代结核病研究人员
基本信息
- 批准号:10431020
- 负责人:
- 金额:$ 99.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-16 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAnimal ModelAreaBaltimoreBasic ScienceBioinformaticsBiological AssayBiometryBiostatistics CoreCessation of lifeClinicalClinical PharmacologyClinical ResearchClinical SciencesClinical TrialsCollaborationsCommunitiesComputer ModelsCost Effectiveness AnalysisCountryDataDevelopmentDiagnosisDiagnosticDisciplineDiseaseEconomic ModelsEducation and OutreachEffectivenessEngineeringEnsureEpidemicEpidemiologyFundingGenerationsGoalsGovernmentHIVHealthHealth Services AccessibilityImageImmunologyIn VitroInterdisciplinary StudyInterventionKnowledgeLaboratoriesMentorsMicrobiologyMissionModelingMycobacterium tuberculosisOutputParticipantPathogenesisPharmaceutical PreparationsPharmacologyPharmacology StudyPoliciesPopulation DynamicsPreventionProductivityProtocols documentationPublic Health NursingResearchResearch PersonnelRoleSamplingScientistServicesSiteSpecific qualifier valueStrategic PlanningSumTalentsTrainingTraining ProgramsTraining SupportTranslational ResearchTuberculosisUnderrepresented PopulationsUnited States National Institutes of HealthUniversitiesWorld Health Organizationanimal imagingbasebiosafety level 3 facilitycareerclinical research sitedesigndiagnostic tooldrug developmentefficacy validationepidemiological modelevidence baseexperienceglobal healthimaging facilitiesimprovedinnovationinterdisciplinary collaborationlarge datasetsmathematical modelmedical schoolsmeetingsmembermicrobialmultidisciplinarynext generationnovelnovel diagnosticspandemic diseasepharmacokinetics and pharmacodynamicspharmacometricspre-clinicalpublic health interventionradiotracerrecruitresearch studysymposiumsynergismtooltraining opportunitytranslational modeltuberculosis treatment
项目摘要
ABSTRACT — JHU TRAC OVERALL
Tuberculosis (TB) remains a major global health problem, and advances in the basic and clinical sciences are
urgently needed to make progress towards the World Health Organization’s End TB Strategy goal of reducing TB
deaths by 95% and new cases by 90% between 2015 and 2035. The Johns Hopkins University (JHU) Center for
Tuberculosis Research (CTR) has been a global leader in TB pathogenesis, translational models, diagnostics, drug
development, pharmacology, public health interventions, and epidemiological and economic modeling for more than
two decades. Research emanating from the CTR and JHU has transformed the treatment of TB infection and
disease, elucidated interactions between TB and HIV drugs, validated the efficacy and effectiveness of new
diagnostic tools, and contributed to the development of evidence-based policies for global TB control, based on the
epidemiology and population dynamics of TB. However, to make further progress in efforts to achieve the END TB
goals, additional innovative, cross-disciplinary and impactful research is critical and a new generation of TB
scientists must be recruited and trained, particularly among groups nationally underrepresented in health-related
research (UHRR). We have assembled a multidisciplinary team of researchers from multiple departments spanning
four JHU schools (Medicine, Public Health, Nursing and Engineering), with complementary expertise in microbial
pathogenesis, immunology, animal models, imaging, clinical trials, diagnostics, epidemiology, pharmacology and
pharmacometrics, computational modeling, and biostatistics, in order to provide added value to the TB research
enterprise at JHU optimize training opportunities for junior investigators and support for new, interdisciplinary
collaborations, with the goal of addressing key knowledge gaps in TB research. The JHU TRAC team comprises
58 researchers, including 32 experienced TB researchers (19 current members of the CTR), 15 senior researchers
new to the TB field, and 11 Early Stage Investigators (ESI). The overarching mission of the JHU TRAC is to advance
TB research by promoting innovative, multidisciplinary collaborations and by recruiting, training and supporting
junior Investigators, especially among UHRR groups, to develop the next generation of leaders in TB research. To
this end, the JHU TRAC will focus on these four areas: 1) Enhance the integration, productivity and impact of JHU
TB research; 2) Provide mentoring, support, and pilot funding for the next generation of TB researchers, and to
increase the pipeline of junior investigators from UHRR groups; 3) Support TB researchers with direct services from
a Clinical Core and three Scientific Cores; 4) Contribute to the END TB goals through global engagement, training,
outreach, and collaboration with partners in high-burden countries. The JHU TRAC is organized into six Cores
(Adminsitrative Core (AC); Developmental Core (DC); Clinical Core (CC); Microbiology, Immunology, Animal
Modeling and Imaging (MIAMI) Core; Pharmacology and Pharmacometrics Core (PPC); and Bioinformatics,
Modeling and Biostatistics Core (BMBC), which will interact closely with each other to promote synergy in TB
research, and ensure that the utility and output of the JHU TRAC is greater than the sum of its parts.
摘要 — JHU TRAC 整体
结核病 (TB) 仍然是一个主要的全球健康问题,基础科学和临床科学的进步正在不断取得进展。
迫切需要在实现世界卫生组织《消灭结核病战略》减少结核病的目标方面取得进展
2015 年至 2035 年间,死亡人数减少 95%,新发病例增加 90%。约翰·霍普金斯大学 (JHU) 中心
结核病研究中心 (CTR) 在结核病发病机制、转化模型、诊断、药物方面一直处于全球领先地位
发展、药理学、公共卫生干预措施以及流行病学和经济模型
二十年来,CTR 和 JHU 的研究改变了结核病感染的治疗方法。
疾病,阐明了结核病和艾滋病毒药物之间的相互作用,验证了新药物的功效和有效性
诊断工具,并为全球结核病控制循证政策的制定做出了贡献
结核病的流行病学和人口动态 然而,要在实现终结结核病的努力中取得进一步进展。
目标,额外的创新、跨学科和有影响力的研究至关重要,新一代结核病
必须招募和培训科学家,特别是在全国卫生相关领域代表性不足的群体中
我们组建了一支由来自多个部门的多学科研究人员组成的团队。
四所约翰霍普金斯大学学院(医学、公共卫生、护理和工程),在微生物方面具有互补的专业知识
发病机制、免疫学、动物模型、影像学、临床试验、诊断、流行病学、药理学和
药理学、计算模型和生物统计学,为结核病研究提供附加值
约翰霍普金斯大学的企业优化了初级研究人员的培训机会,并为新的跨学科提供支持
JHU TRAC 团队的成员包括:
58名研究人员,其中32名经验丰富的结核病研究人员(19名现任CTR成员),15名高级研究人员
JHU TRAC 的首要任务是推动结核病领域的发展。
通过促进创新、多学科合作以及招募、培训和支持来开展结核病研究
初级研究人员,特别是 UHRR 小组中的初级研究人员,培养结核病研究的下一代领导者。
为此,JHU TRAC 将重点关注以下四个领域: 1)增强 JHU 的一体化、生产力和影响力
结核病研究;2) 为下一代结核病研究人员提供指导、支持和试点资金,并
增加 UHRR 小组的初级研究人员队伍;3) 通过直接服务支持结核病研究人员
一个临床核心和三个科学核心;4) 通过全球参与、培训、
JHU TRAC 分为六个核心。
(行政核心(AC);发展核心(DC);临床核心(CC);微生物学、免疫学、动物学
建模和成像(MIAMI)核心;药理学和药理学核心(PPC)和生物信息学;
建模和生物统计核心(BMBC),它们将相互密切相互作用,以促进结核病的协同作用
研究,并确保 JHU TRAC 的效用和产出大于其各个部分的总和。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard E. Chaisson其他文献
Richard E. Chaisson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard E. Chaisson', 18)}}的其他基金
JHU TRAC: Training and Supporting the Next Generation of TB Researchers
JHU TRAC:培训和支持下一代结核病研究人员
- 批准号:
10593142 - 财政年份:2022
- 资助金额:
$ 99.66万 - 项目类别:
JHU TRAC: Training and Supporting the Next Generation of TB Researchers
JHU TRAC:培训和支持下一代结核病研究人员
- 批准号:
10593142 - 财政年份:2022
- 资助金额:
$ 99.66万 - 项目类别:
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
超短疗程利福喷丁和异烟肼 (1HP) 用于预防未感染 HIV 个体结核病的安全性和耐受性
- 批准号:
10018455 - 财政年份:2020
- 资助金额:
$ 99.66万 - 项目类别:
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
超短疗程利福喷丁和异烟肼 (1HP) 用于预防未感染 HIV 个体结核病的安全性和耐受性
- 批准号:
10413161 - 财政年份:2020
- 资助金额:
$ 99.66万 - 项目类别:
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
超短疗程利福喷丁和异烟肼 (1HP) 用于预防未感染 HIV 个体结核病的安全性和耐受性
- 批准号:
10226377 - 财政年份:2020
- 资助金额:
$ 99.66万 - 项目类别:
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
超短疗程利福喷丁和异烟肼 (1HP) 用于预防 HIV 未感染者结核病的安全性和耐受性
- 批准号:
10631078 - 财政年份:2020
- 资助金额:
$ 99.66万 - 项目类别:
The Johns Hopkins Center for AIDS Research (JHU CFAR)
约翰霍普金斯大学艾滋病研究中心 (JHU CFAR)
- 批准号:
10268586 - 财政年份:2020
- 资助金额:
$ 99.66万 - 项目类别:
The Johns Hopkins Center for AIDS Research (JHU CFAR)
约翰霍普金斯大学艾滋病研究中心 (JHU CFAR)
- 批准号:
10458357 - 财政年份:2012
- 资助金额:
$ 99.66万 - 项目类别:
The Johns Hopkins Center for AIDS Research (JHU CFAR)
约翰霍普金斯大学艾滋病研究中心 (JHU CFAR)
- 批准号:
9322787 - 财政年份:2012
- 资助金额:
$ 99.66万 - 项目类别:
The Johns Hopkins Center for AIDS Research (JHU CFAR)
约翰霍普金斯大学艾滋病研究中心 (JHU CFAR)
- 批准号:
8653924 - 财政年份:2012
- 资助金额:
$ 99.66万 - 项目类别:
相似国自然基金
髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
- 批准号:82372496
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
探索在急性呼吸窘迫综合征动物模型和患者长时间俯卧位通气过程中动态滴定呼气末正压的意义
- 批准号:82270081
- 批准年份:2022
- 资助金额:76 万元
- 项目类别:面上项目
雌激素抑制髓系白血病动物模型中粒细胞异常增生的机制
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于中医经典名方干预效应差异的非酒精性脂肪性肝病动物模型证候判别研究
- 批准号:
- 批准年份:2022
- 资助金额:53 万元
- 项目类别:面上项目
无菌动物模型与单细胞拉曼技术结合的猴与人自闭症靶标菌筛选及其机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Predictive Markers for Longitudinal TMJ Integrity
纵向颞下颌关节完整性的预测标记
- 批准号:
10648171 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
Postnatal and Prenatal Therapeutic Base Editing for Metabolic Diseases
代谢性疾病的产后和产前治疗碱基编辑
- 批准号:
10668614 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
Gain-of-function complement activators as a new class of immunotherapeutic molecules
功能获得性补体激活剂作为一类新型免疫治疗分子
- 批准号:
10629623 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别:
In vivo label free optical imaging of immune cells in human skin
人体皮肤免疫细胞体内无标记光学成像
- 批准号:
10664746 - 财政年份:2023
- 资助金额:
$ 99.66万 - 项目类别: